Literature DB >> 22098792

Methods of verifying the output of the treatment planning system used for high dose rate (HDR) prostate brachytherapy.

Aaron Huckle1, Bashar Al-Qaisieh, Peter Bownes.   

Abstract

OBJECTIVES: To investigate the relationships between the planning target volume (PTV) and the total reference air kerma (TRAK) required to irradiate the prostate using the Nucletron microSelection (192)Ir radioactive stepping source afterloader for the treatment of prostate cancer.
METHODS: Using 54 patient plans, the relationship between the treatment planning system (TPS) TRAK (TRAK(TPS)) and the estimate and planimetry prostate volumes was investigated. Linear regression analysis was used to predict the TRAK (TRAK(pred)) using the prostate gland height, width and length (HWL) measurements. The TRAK was corrected using a conformal index (COIN) of the plan to improve the accuracy of the model. A further 54 patient plans were then used to evaluate the outcome of the linear regression lines.
RESULTS: A formula was proposed (HxWxLxπ/5.19) to estimate the prostate volume, which showed a mean deviation from the planimetry volume of 0.0139 ± 3.339 cm(3), where 69% was within ± 10% of planimetry, and 96% within ±20%. Scatter graphs of TRAK(TPS) for 54 plans, showed a positive linear correlation, r=0.98, using the planimetry volume, and r=0.95 for the estimated volume. The further 54 treatment plans used for evaluation showed the TRAK(pred) was accurately predicted to ± 10% for 100% of plans using the planimetry volume and 81% using the prostate volume estimate.
CONCLUSIONS: The verification method proposed was found to be accurate and independent of TPS parameters, with suitable acceptance margins of ± 10%.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22098792     DOI: 10.1016/j.radonc.2011.09.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  1 in total

1.  Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy.

Authors:  Xiaojuan Yu; Jin Li; Xiaoming Zhong; Jingdong He
Journal:  BMC Cancer       Date:  2015-10-06       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.